Crohn's disease trials in Mexico

In Mexico 6 Also abroad 422

6 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Benito Juarez Ciudad de Mexico, Chihuahua City, Cuernavaca, León, Mérida, Mexico City, Monterrey, Oaxaca City, San Pedro Garza García, Tlajomulco de Zúñiga
Age
16 years to 80 years
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
Phase 3Taking people
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Where
Mexico City, Veracruz
Age
2 years to 17 years
People
100 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07298421 · EU 2025-523318-96-00
Phase 2Taking people
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Where
Durango, Irapuato, Jalisco, Mérida, Mexico City, Distrito Federal, Morelia, Oaxaca City, Querétaro
Age
18 years to 85 years
People
385 worldwide
Run by
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
See details and how to joinNCT06226883 · EU 2023-508158-24-00
Phase 3Taking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Aguascalientes, Chihuahua City, Ciudad Madero, Durango, Guadajalara, Guadalajara, Juriquilla, Mérida, Mexico City, Monterrey, Morelia, Puebla City, Tlalnepantla, Veracruz
Age
18 years to 70 years
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
Phase 3Taking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Jalisco, Monterrey, Veracruz
Age
16 years to 80 years
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Guadalajara, Mérida, Mexico
Age
16 years to 80 years
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00